Hemcheck Sweden AB has signed a three year distribution agreement with Al Shomoukh Trading for Technical & Medical Supplies EST (”Astemed”), one of the leading distributors of medical equipment in the UAE, with operations across the Middle East and Northern Africa. The earlier evaluation agreement with Gulf Drug has been canceled.

– Astemed is a large and well-established distributor in the region and has a profile and an ambition that fits Hemcheck very well. We hope that the collaboration will be successful and look forward to commencing the work together with Astemed, says Joen Averstad, CEO of Hemcheck.

– We are very happy to start this collaboration with Hemcheck, and we believe the products have good potential in the market. We look forward to starting the marketing and sales work with our customers, says Ashraf Naguib, Vice president at Astemed.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About Astemed

Astemed was founded in 2003 with its head office located in Abu Dhabi. It’s one of the leading distributors of medical and laboratory equipment in the UAE and across the Middle East. Astemed specializes in several areas such as emergency medicine, intensive care, cardiology, etc. and is a partner to global manufacturers such as Werfen.

Read more at: https://astemed.com/

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.